Jamieson Wellness Inc. Reports Second Quarter 2023 Results and Raises Second Quarter Dividend

 

  Consolidated revenue increased 49.6% to $167.6 million; Jamieson Brands revenue increased 51.5%; Adjusted EBITDA 1 increased 27.1% or $6.6 million to $31.1 million  

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported its second quarter results for the period ended June 30, 2023. All amounts are expressed in Canadian dollars.

 

"Consumers globally remain committed to supporting their health and wellness needs, as evidenced by the continued demand for our products during the second quarter," said Mike Pilato, President and CEO of Jamieson Wellness. "Consumer consumption continued to be strong, and with the inclusion of the youtheory brand our Jamieson Brands revenue increased more than 50%. Adjusted EBITDA in the quarter increased by 27%, as we continued to integrate youtheory, build our owned model in China, and invest to support our growth across the business.

 

"Jamieson Wellness is a much different company than it was just a few years ago, as we now operate on a larger scale and in the distinct business units of Canada, U.S., China and International to better support our organizational aspirations. Our ability to consistently deliver growth while also adjusting to the fluctuating global macro-economic environment is a testament to the strength of our team and our strategy.

 

"From a guidance perspective, we are maintaining our full year growth expectations for the U.S. and China, our key strategic pillars, while adjusting the top-end of our revenue guidance from +28% to +26% and Adjusted EBITDA from +18% to +16% to reflect the post-pandemic situation we are seeing in Canada and in a few International markets. Continued strong Canadian consumption growth is expected to be partially offset by adjusted inventories in trade as certain retailers manage their working capital investments.

 

"Overall, we are proud of our performance in the quarter, and pleased to announce an 11.8% increase in our dividend as we continue to drive value for all our stakeholders. Our growth in 2023 continues to be strong as our transformation this year sets us up for continued long-term success."

 

  Second Quarter Highlights  

 
  • Solid growth in Canada as consumer consumption significantly outpaced shipments in both units and dollars
  •  
  • Youtheory met revenue expectations; new products including new and improved turmeric SKU began shipping
  •  
  • Maintained strong growth momentum in China while successfully closing previously announced DCP Capital ("DCP") transaction and completing transition to an owned distribution model
  •  
  • Consumer patterns in Eastern Europe continued to stabilize with 5.0% growth in consumption
  •  
  • Began implementation of new environmental management system to track scope 1 & 2 greenhouse gas emission for 2024 reporting
  •  

  Second Quarter Financial Results Consolidated Summary  

 

All comparisons are with the second quarter of 2022

 
  • Consolidated revenue increased 49.6% to $167.6 million with both Jamieson Brands and Strategic Partners segments contributing to growth
  •  
  • Gross profit increased by $14.2 million to $54.9 million largely driven by higher organic and acquired revenue; Gross profit margin 3 decreased by 370 basis points to 32.7% due to the inherently lower youtheory margin profile
  •  
  • EBITDA 1 increased $3.5 million or 18.6% to $22.3 million; Adjusted EBITDA 1 increased by $6.6 million or 27.1% to $31.1 million. Adjusted EBITDA includes adjustments mainly related to investments associated with acquisitions, the Company's strategic partnership in China, and certain IT implementation costs
  •  
  • Net earnings decreased 28.6% to $7.2 million; Adjusted net earnings 1 increased 1.6% to $13.6 million due to the impact of higher revenues and gross profit, offset by selling, general and administrative and marketing investments in the U.S. and China to set the foundation for future growth, and increased borrowing costs
  •  
  • Diluted earnings per share was $0.17; Adjusted diluted earnings per share 2 was $0.32
  •  

  Summary of Segment Results  

 

All comparisons are with the second quarter of 2022

 

  Jamieson Brands  

 
  • Revenue was $132.9 million, an increase of 51.5% or $45.2 million
  •  
  • Organic Jamieson Brands revenue increased 3.6%
  •  
  • Canada revenue increased 2.0% as consumer consumption remained strong and outpaced shipments
  •  
  • U.S. (youtheory) contributed $42.1 million in revenue driven by innovation, strength of e-commerce, and distribution gains
  •  
  • China revenue grew 63.0%, representing the first period of sales under the new Jamieson-owned distribution model, or 21.0% on a pro-forma basis, driven by continued strong demand in cross border e-commerce, club sales, and new distribution
  •  
  • International revenue declined $2.2 million reflecting a general slowdown in regulatory approvals as international governments work through pandemic backlogs, and timing of customer inventory replenishment, while consumption remained strong across many geographic regions including 5.0% growth in Eastern Europe
  •  
  • Gross profit increased $11.8 million to $49.7 million due to higher revenue; gross profit margin 3 decreased by 580 basis points largely driven by the inherently lower youtheory margin profile
  •  
  • Adjusted EBITDA 1 increased $4.1 million to $26.7 million driven by higher revenue and gross profit partially offset by previously noted investments in SG&A related to the U.S. and China; Adjusted EBITDA margin 2 decreased by 560 basis points to 20.1% due to youtheory's inherently lower gross profit margin and the seasonal weighting of youtheory volumes
  •  

  Strategic Partners  

 
  • Revenue was $34.7 million, an increase of 42.8% or $10.4 million, driven by the impact of higher pricing, available production capacity, and order timing
  •  
  • Gross profit increased $2.3 million to $5.1 million; gross profit margin 3 increased by 310 basis points to 14.8% due to timing of volume driven operating efficiencies and mix
  •  
  • Adjusted EBITDA 1 increased by $2.5 million to $4.4 million; Adjusted EBITDA margin 2 increased by 490 basis points to 12.7%
  •  

  Balance Sheet and Cash Flow  

 
  • The Company generated $11.7 million in cash from operations compared to $13.3 million in Q2 2022
  •  
  • Cash from operating activities before working capital considerations of $12.7 million decreased by $4.2 million compared to Q2 2022 due to transaction related expenses, the Company's strategic partnership in China, and system implementation costs
  •  
  • Cash used in working capital decreased by $2.5 million compared to Q2 2022 driven by timing of accounts receivable collections and payables in the quarter
  •  
  • As at June 30, 2023, the Company had approximately $246.2 million in cash and available revolving facilities and net debt 1 of $253.8 million
  •  

  1 This is a non-IFRS financial measure. See the "Non-IFRS and Other Financial Measures" section of this press release for more information on each non-IFRS financial measure.
2 This is a non-IFRS ratio. See the "Non-IFRS and Other Financial Measures" section of this press release for more information on each non-IFRS ratio.
3 This is a supplementary financial measure. See the "Non-IFRS and Other Financial Measures" section of this press release for more information on each supplementary financial measure.

 

  Fiscal 2023 Outlook  

 

Consumer consumption continues to be strong across the organization, and the Company is maintaining its previous growth expectations in both its United States and China business units. In Canada, strong consumer consumption continues to outpace shipments while retailers have begun to reduce their investments in working capital. With lower shipments in Canada and regulatory timing impacting International, the Company has decided to trim the top end of its guidance range in Jamieson Brands revenue and profitability.

 

The Company now anticipates the following:

 
  • Consolidated fiscal 2023 revenue to range between $670.0 and $690.0 million (+22.0% to +26.0%) from a previous range of +22% to +28%
  •  
  • Jamieson Canada revenue growth of 2.0% to 4.0% (updated from 3.0% to 6.0%). Consumer consumption remains strong, reflecting continued consumer prioritization of their health and wellness offset by reduced inventory levels within customer and distributor partners as they lower working capital investments in response to higher costs of capital.
  •  
  • Jamieson International revenue of between flat and 10% growth (updated from 5.0% to 20.0%), reflecting a post COVID-19 government slowdown of processing product registrations in new and existing markets. The Company's revised outlook continues to be driven by marketing, innovation and the timing of distribution into new markets.
  •  
  • Adjusted EBITDA to range from $140.0 to $144.0 million (+13.0% to +16.0%) from the previous range of +13% to +18%
  •  
  • Adjusted diluted earnings per share to range from $1.56 to $1.63 (flat to +5.2%), updated from the previous range of $1.62 to $1.72, reflecting revisions to the Company's revenue outlook along with higher prevailing interest rates and the timing of cash flows associated with the Company's partnership in China
  •  

The Company's guidance continues to reflect an accelerated investment in marketing, resources, and infrastructure to support long-term growth opportunities in the United States and in China. The Company continues to anticipate:

 
  • Youtheory revenue of between $145.0 and $155.0 million (unchanged) with growth driven by product innovation, expanded e-commerce initiatives and distribution gains
  •  
  • Jamieson China revenue growth of between 65.0% to 75.0% (unchanged), reflecting the transition to an owned distribution model completed in the second quarter and the related step-up to distributor level pricing, along with continued consumer demand in cross border e-commerce and distribution gains in the domestic retail channels
  •  

For additional details on the Company's fiscal 2023 outlook, including guidance for the third quarter of 2023, refer to the "Outlook" section in the management's discussion and analysis of financial condition and results of operations ("MD&A") for the three and six months ended June 30, 2023.

 

  Declaration of Second Quarter Dividend  

 

The board of directors of the Company authorized a 2.0 cent or an 11.8% increase in the quarterly dividend and declared a cash dividend for the second quarter of 2023:

 
  • $0.19 per common share, or approximately $8.0 million in the aggregate
  •  
  • Paid on September 15, 2023 to all common shareholders of record at the close of business on September 1, 2023
  •  
  • The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada)
  •  

  Consolidated Financial Statements and Management's Discussion and Analysis  

 

The Company's unaudited condensed consolidated interim financial statements and accompanying notes as at and for the three and six months ended June 30, 2023 and related MD&A are available under the Company's profile on SEDAR at   www.sedar.com   and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com .

 

  Conference Call  

 

Management will host a conference call to discuss the Company's second quarter 2023 results at 5:00 p.m. ET today, August 3, 2023. To access:

 

  About Jamieson Wellness  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

 

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2023 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2023 and under the "Risk Factors" section in the MD&A filed today, August 3, 2023. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 
                                                                                                                                                                                                                                                                                                                                                                                              
 
 

  Jamieson Wellness Inc.
Selected Consolidated Financial Information
In thousands of Canadian dollars, except share and per share amounts

 
 
 
    Three months ended     Six months ended  
    June 30     June 30  
   

  2023  

 
  

  2022  

 
  

  2023  

 
  

  2022  

 
         
  Revenue    

  167,577  

 
  

  111,990  

 
  

  304,302  

 
  

  215,665  

 
Cost of sales   

112,711

 
  

71,277

 
  

200,920

 
  

137,005

 
Gross profit   

54,866

 
  

40,713

 
  

103,382

 
  

78,660

 
         
  Gross profit margin    

  32.7%  

 
  

  36.4%  

 
  

  34.0%  

 
  

  36.5%  

 
         
Selling, general and administrative expenses   

34,832

 
  

24,996

 
  

67,224

 
  

46,616

 
Share-based compensation   

1,425

 
  

1,136

 
  

2,921

 
  

2,278

 
  Earnings from operations    

  18,609  

 
  

  14,581  

 
  

  33,237  

 
  

  29,766  

 
         
  Operating margin    

  11.1%  

 
  

  13.0%  

 
  

  10.9%  

 
  

  13.8%  

 
         
Foreign exchange loss (gain)   

1,482

 
  

(413)

 
  

1,645

 
  

50

 
Interest expense and other financing costs   

6,008

 
  

1,238

 
  

12,310

 
  

2,516

 
Accretion on preferred shares   

827

 
  

-

 
  

827

 
  

-

 
Earnings before income taxes   

10,292

 
  

13,756

 
  

18,455

 
  

27,200

 
Provision for income taxes   

3,088

 
  

3,662

 
  

4,186

 
  

7,365

 
  Net earnings    

  7,204  

 
  

  10,094  

 
  

  14,269  

 
  

  19,835  

 
         
  Net earnings attributable to:          
Shareholders   

8,186

 
  

10,094

 
  

15,251

 
  

19,835

 
Non-controlling interests   

(982)

 
  

-

 
  

(982)

 
  

-

 
   

  7,204  

 
  

  10,094  

 
  

  14,269  

 
  

  19,835  

 
  Adjusted net earnings    

  13,632  

 
  

  13,415  

 
  

  22,478  

 
  

  24,159  

 
         
  EBITDA    

  22,277  

 
  

  18,785  

 
  

  41,583  

 
  

  37,223  

 
  Adjusted EBITDA    

  31,056  

 
  

  24,439  

 
  

  55,564  

 
  

  45,384  

 
         
  Adjusted EBITDA margin    

  18.5%  

 
  

  21.8%  

 
  

  18.3%  

 
  

  21.0%  

 
         
  Weighted average number of shares          
Basic   

41,943,971

 
  

40,461,610

 
  

41,860,444

 
  

40,451,991

 
Diluted   

42,890,029

 
  

41,919,787

 
  

42,745,685

 
  

41,877,072

 
         
  Earnings per share attributable to common shareholders:          
Basic, earnings per share   

0.17

 
  

0.25

 
  

0.34

 
  

0.49

 
Diluted, earnings per share   

0.17

 
  

0.24

 
  

0.33

 
  

0.47

 
Adjusted diluted, earnings per share   

0.32

 
  

0.32

 
  

0.53

 
  

0.58

 
         
 
                                                                                                                                                                                                                        
 
 

  Jamieson Wellness Inc.
Consolidated Statements of Financial Position
In thousands of Canadian dollars

 
     
     
    June 30,
2023
 
   December 31,
2022
 
  Assets      
  Current assets      
Cash   

91,375

 
  

26,240

 
Accounts receivable   

109,422

 
  

160,798

 
Inventories   

208,523

 
  

154,488

 
Derivatives   

6,071

 
  

6,580

 
Prepaid expenses and other current assets   

6,305

 
  

4,298

 
   

  421,696  

 
  

  352,404  

 
  Non-current assets      
Property, plant and equipment   

109,921

 
  

111,709

 
Goodwill   

272,815

 
  

272,916

 
Intangible assets   

368,930

 
  

367,205

 
Deferred income tax   

4,109

 
  

3,029

 
  Total assets    

  1,177,471  

 
  

  1,107,263  

 
     
  Liabilities      
  Current liabilities      
Accounts payable and accrued liabilities   

130,459

 
  

142,566

 
Income taxes payable   

2,742

 
  

7,387

 
Current portion of other long-term liabilities   

4,649

 
  

4,852

 
   

  137,850  

 
  

  154,805  

 
  Long-term liabilities      
Long-term debt   

345,146

 
  

400,000

 
Post-retirement benefits   

985

 
  

929

 
Deferred income tax   

59,347

 
  

58,007

 
Redeemable preferred shares   

85,940

 
  

-

 
Other long-term liabilities   

60,017

 
  

61,931

 
  Total liabilities    

  689,285  

 
  

  675,672  

 
     
  Equity      
Share capital   

313,107

 
  

307,200

 
Warrants   

14,705

 
  

-

 
Contributed surplus   

17,525

 
  

17,115

 
Retained earnings   

86,495

 
  

85,483

 
Accumulated other comprehensive income   

13,655

 
  

21,793

 
  Total shareholders' equity    

  445,487  

 
  

  431,591  

 
Non-controlling interests   

42,699

 
  

-

 
  Total equity    

  488,186  

 
  

  431,591  

 
  Total liabilities and equity    

  1,177,471  

 
  

  1,107,263  

 
     
 

  Non-IFRS and Other Financial Measures  

 

This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. The Company uses the following non‑IFRS financial measures: "EBITDA", "Adjusted EBITDA" and "Adjusted net earnings", the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, "normalized gross profit", "normalized SG&A", "normalized earnings from operations", "cash from operating activities before working capital considerations" and "net debt", the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: "Adjusted EBITDA margin", "Adjusted diluted earnings per share", "normalized gross profit margin", "normalized operating margin", and the following supplementary financial measures: "gross profit margin" and "operating margin" to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non‑IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the " How we Assess the Performance of our Business " section of the MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company's financial statements to which the measure relates.

 

The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as gross profit to normalized gross profit, SG&A to normalized SG&A, earnings from operations to normalized earnings from operations, each of which are non-IFRS financial measures (see the " Non-IFRS and Other Financial Measures " of this press release for further information on each non-IFRS financial measure) for the three and six months ended June 30, 2023 and June 30, 2022.

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
 

  Jamieson Wellness Inc.
Segment Information
In thousands of Canadian dollars, except as otherwise noted

 
         
         
  Jamieson Brands          
          
     Three months ended
June 30
 
    
    

  2023  

 
  

  2022  

 
   $ Change     % Change  
          
  Revenue   

132,916

 
  

87,715

 
  

45,201

 
  

51.5%

 
          
  Gross profit   

49,719

 
  

37,875

 
  

11,844

 
  

31.3%

 
  Amortization of fair value adjustments   

2,315

 
  

-

 
  

2,315

 
  

100.0%

 
  Normalized gross profit   

52,034

 
  

37,875

 
  

14,159

 
  

37.4%

 
          
  Gross profit margin   

37.4%

 
  

43.2%

 
  

-

 
  

(5.8%)

 
  Normalized gross profit margin   

39.1%

 
  

43.2%

 
  

-

 
  

(4.1%)

 
          
  Share-based compensation (1)   

1,425

 
  

1,136

 
  

289

 
  

25.4%

 
          
  Selling, general and administrative expenses   

33,279

 
  

23,448

 
  

9,831

 
  

41.9%

 
  Acquisition and divestiture related costs (2)   

(2,307)

 
  

(3,484)

 
  

1,177

 
  

33.8%

 
  IT system implementation (3)   

(1,429)

 
  

(1,436)

 
  

7

 
  

0.5%

 
  Other   

179

 
  

(11)

 
  

190

 
  

1727.3%

 
  Normalized selling, general and administrative expenses   

29,722

 
  

18,517

 
  

11,205

 
  

60.5%

 
          
   Earnings from operations    

  15,015  

 
  

  13,291  

 
  

  1,724  

 
  

  13.0%  

 
  Acquisition and divestiture related costs (2)   

2,307

 
  

3,484

 
  

(1,177)

 
  

(33.8%)

 
  IT system implementation (3)   

1,429

 
  

1,436

 
  

(7)

 
  

(0.5%)

 
  Amortization of fair value adjustments (4)   

2,315

 
  

-

 
  

2,315

 
  

100.0%

 
  Other   

(179)

 
  

11

 
  

(190)

 
  

(1727.3%)

 
   Normalized earnings from operations    

  20,887  

 
  

  18,222  

 
  

  2,665  

 
  

  14.6%  

 
          
   Operating margin    

  11.3%  

 
  

  15.2%  

 
  

  -  

 
  

  (3.9%)  

 
   Normalized operating margin    

  15.7%  

 
  

  20.8%  

 
  

  -  

 
  

  (5.1%)  

 
          
   Adjusted EBITDA    

  26,656  

 
  

  22,557  

 
  

  4,099  

 
  

  18.2%  

 
   Adjusted EBITDA margin    

  20.1%  

 
  

  25.7%  

 
  

  -  

 
  

  (5.6%)  

 
          
          
  Strategic Partners          
          
     Three months ended
June 30
 
    
    

  2023  

 
  

  2022  

 
   $ Change     % Change  
          
  Revenue   

34,661

 
  

24,275

 
  

10,386

 
  

42.8%

 
          
  Gross profit   

5,147

 
  

2,838

 
  

2,309

 
  

81.4%

 
  Gross profit margin   

14.8%

 
  

11.7%

 
  

-

 
  

3.1%

 
          
  Selling, general and administrative expenses   

1,553

 
  

1,548

 
  

5

 
  

0.3%

 
          
   Earnings from operations    

  3,594  

 
  

  1,290  

 
  

  2,304  

 
  

  178.6%  

 
   Operating margin    

  10.4%  

 
  

  5.3%  

 
  

  -  

 
  

  5.1%  

 
          
   Adjusted EBITDA    

  4,400  

 
  

  1,882  

 
  

  2,518  

 
  

  133.8%  

 
   Adjusted EBITDA margin    

  12.7%  

 
  

  7.8%  

 
  

  -  

 
  

  4.9%  

 
          
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
 

  Jamieson Wellness Inc.
Segment Information (continued)
In thousands of Canadian dollars, except as otherwise noted

 
         
         
  Jamieson Brands          
          
     Six months ended
June 30
 
    
    

  2023  

 
  

  2022  

 
   $ Change     % Change  
          
  Revenue   

241,026

 
  

170,903

 
  

70,123

 
  

41.0%

 
          
  Gross profit   

93,520

 
  

73,492

 
  

20,028

 
  

27.3%

 
  Amortization of fair value adjustments (4)   

2,315

 
  

-

 
  

2,315

 
  

100.0%

 
  Normalized gross profit   

95,835

 
  

73,492

 
  

22,343

 
  

30.4%

 
          
  Gross profit margin   

38.8%

 
  

43.0%

 
  

-

 
  

(4.2%)

 
  Normalized gross profit margin   

39.8%

 
  

43.0%

 
  

-

 
  

(3.2%)

 
          
  Share-based compensation (1)   

2,921

 
  

2,278

 
  

643

 
  

28.2%

 
          
  Selling, general and administrative expenses   

63,942

 
  

43,499

 
  

20,443

 
  

47.0%

 
  Acquisition and divestiture related costs (2)   

(5,108)

 
  

(3,484)

 
  

(1,624)

 
  

(46.6%)

 
  IT system implementation (3)   

(2,099)

 
  

(2,175)

 
  

76

 
  

3.5%

 
  Other   

179

 
  

(127)

 
  

306

 
  

240.9%

 
  Normalized selling, general and administrative expenses   

56,914

 
  

37,714

 
  

19,200

 
  

50.9%

 
          
   Earnings from operations    

  26,657  

 
  

  27,715  

 
  

  (1,058)  

 
  

  (3.8%)  

 
  Acquisition and divestiture related costs (2)   

5,108

 
  

3,484

 
  

1,624

 
  

46.6%

 
  IT system implementation (3)   

2,099

 
  

2,175

 
  

(76)

 
  

(3.5%)

 
  Amortization of fair value adjustments (4)   

2,315

 
  

-

 
  

2,315

 
  

(100.0%)

 
  Other   

(179)

 
  

127

 
  

(306)

 
  

(240.9%)

 
   Normalized earnings from operations    

  36,000  

 
  

  33,500  

 
  

  2,500  

 
  

  7.5%  

 
          
   Operating margin    

  11.1%  

 
  

  16.2%  

 
  

  -  

 
  

  (5.1%)  

 
   Normalized operating margin    

  14.9%  

 
  

  19.6%  

 
  

  -  

 
  

  (4.7%)  

 
          
   Adjusted EBITDA    

  47,307  

 
  

  42,097  

 
  

  5,210  

 
  

  12.4%  

 
   Adjusted EBITDA margin    

  19.6%  

 
  

  24.6%  

 
  

  -  

 
  

  (5.0%)  

 
          
          
  Strategic Partners          
          
     Six months ended
June 30
 
    
    

  2023  

 
  

  2022  

 
   $ Change     % Change  
          
  Revenue   

63,276

 
  

44,762

 
  

18,514

 
  

41.4%

 
          
  Gross profit   

9,862

 
  

5,168

 
  

4,694

 
  

90.8%

 
  Gross profit margin   

15.6%

 
  

11.5%

 
  

-

 
  

4.1%

 
          
  Selling, general and administrative expenses   

3,282

 
  

3,117

 
  

165

 
  

5.3%

 
  Other   

(72)

 
  

(47)

 
  

(25)

 
  

(53.2%)

 
  Normalized selling, general and administrative expenses   

3,210

 
  

3,069

 
  

141

 
  

4.6%

 
          
   Earnings from operations    

  6,580  

 
  

  2,051  

 
  

  4,529  

 
  

  220.8%  

 
  Other   

72

 
  

47

 
  

25

 
  

53.2%

 
   Normalized earnings from operations    

  6,652  

 
  

  2,099  

 
  

  4,553  

 
  

  216.9%  

 
          
   Operating margin    

  10.4%  

 
  

  4.6%  

 
  

  -  

 
  

  5.8%  

 
   Normalized operating margin    

  10.5%  

 
  

  4.7%  

 
  

  -  

 
  

  5.8%  

 
          
   Adjusted EBITDA    

  8,257  

 
  

  3,287  

 
  

  4,970  

 
  

  151.2%  

 
   Adjusted EBITDA margin    

  13.0%  

 
  

  7.3%  

 
  

  -  

 
  

  5.7%  

 
          
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
 
 

  Reconciliation of Non-IFRS Financial Measures
In thousands of Canadian dollars

 
 
 
    Three months ended     Six months ended  
    June 30     June 30  
  ($ in 000's, except as otherwise noted)    

  2023  

 
  

  2022  

 
  

  2023  

 
  

  2022  

 
         
  Net earnings:    

  7,204  

 
  

  10,094  

 
  

  14,269  

 
  

  19,835  

 
  Add:          
Provision for income taxes   

3,088

 
  

3,662

 
  

4,186

 
  

7,365

 
Interest expense and other financing costs   

6,008

 
  

1,238

 
  

12,310

 
  

2,516

 
Accretion on preferred shares   

827

 
  

-

 
  

827

 
  

-

 
Depreciation of property, plant, and equipment   

3,659

 
  

2,722

 
  

7,126

 
  

5,380

 
Amortization of intangible assets   

1,491

 
  

1,069

 
  

2,865

 
  

2,127

 
         
  Earnings before interest, taxes, depreciation, and amortization (EBITDA)    

  22,277  

 
  

  18,785  

 
  

  41,583  

 
  

  37,223  

 
Share-based compensation   

1,425

 
  

1,136

 
  

2,921

 
  

2,278

 
Foreign exchange loss (gain)   

1,482

 
  

(413)

 
  

1,645

 
  

50

 
Acquisition and divestiture related costs   

2,307

 
  

3,484

 
  

5,108

 
  

3,484

 
Amortization of fair value adjustments   

2,315

 
  

-

 
  

2,315

 
  

-

 
IT system implementation   

1,429

 
  

1,436

 
  

2,099

 
  

2,175

 
Other   

(179)

 
  

11

 
  

(107)

 
  

174

 
  Adjusted EBITDA    

  31,056  

 
  

  24,439  

 
  

  55,564  

 
  

  45,384  

 
Provision for income taxes   

(3,088)

 
  

(3,662)

 
  

(4,186)

 
  

(7,365)

 
Interest expense and other financing costs   

(6,008)

 
  

(1,238)

 
  

(12,310)

 
  

(2,516)

 
Depreciation of property, plant, and equipment   

(3,659)

 
  

(2,722)

 
  

(7,126)

 
  

(5,380)

 
Amortization of intangible assets   

(1,491)

 
  

(1,069)

 
  

(2,865)

 
  

(2,127)

 
Share-based compensation (5)   

(1,303)

 
  

(1,136)

 
  

(2,757)

 
  

(2,278)

 
Tax deduction from vesting of certain share-based awards (6)   

-

 
  

-

 
  

(1,022)

 
  

-

 
Tax effect of normalization adjustments   

(1,875)

 
  

(1,197)

 
  

(2,820)

 
  

(1,559)

 
  Adjusted net earnings    

  13,632  

 
  

  13,415  

 
  

  22,478  

 
  

  24,159  

 
         
         
    Three months ended     Six months ended  
    June 30     June 30  
   

  2023  

 
  

  2022  

 
  

  2023  

 
  

  2022  

 
         
  Gross profit    

  54,866  

 
  

  40,713  

 
  

  103,382  

 
  

  78,660  

 
Amortization of fair value adjustments   

2,315

 
  

-

 
  

2,315

 
  

-

 
  Normalized gross profit    

  57,181  

 
  

  40,713  

 
  

  105,697  

 
  

  78,660  

 
  Normalized gross profit margin    

  34.1%  

 
  

  36.4%  

 
  

  34.7%  

 
  

  36.5%  

 
         
  Selling, general and administrative expenses    

  34,832  

 
  

  24,996  

 
  

  67,224  

 
  

  46,616  

 
Acquisition and divestiture related costs   

(2,307)

 
  

(3,484)

 
  

(5,108)

 
  

(3,484)

 
IT system implementation   

(1,429)

 
  

(1,436)

 
  

(2,099)

 
  

(2,175)

 
Other   

179

 
  

(11)

 
  

107

 
  

(174)

 
  Normalized selling, general and administrative expenses    

  31,275  

 
  

  20,065  

 
  

  60,124  

 
  

  40,783  

 
         
  Earnings from operations    

  18,609  

 
  

  14,581  

 
  

  33,237  

 
  

  29,766  

 
Acquisition and divestiture related cost   

2,307

 
  

3,484

 
  

5,108

 
  

3,484

 
IT system implementation   

1,429

 
  

1,436

 
  

2,315

 
  

-

 
Amortization of fair value adjustments   

2,315

 
  

-

 
  

2,099

 
  

2,175

 
Other   

(179)

 
  

11

 
  

(107)

 
  

174

 
  Normalized earnings from operations    

  24,481  

 
  

  19,512  

 
  

  42,652  

 
  

  35,599  

 
  Normalized operating margin    

  14.6%  

 
  

  17.4%  

 
  

  14.0%  

 
  

  16.5%  

 
         
 
                                 
 

(1)

 
  

The Company's share-based compensation expense pertains to our long-term incentive plan (the "LTIP"), with performance-based share units ("PSUs"), time-based restricted share units ("RSUs"), and deferred share units ("DSUs") expenses, along with associated payroll taxes.

 
   
 

(2)

 
  

Current period expense mainly pertains to legal and consulting costs associated with the acquisition of our former distributor partner in China on April 28, 2023, and costs associated with the completion of our transaction with DCP on May 16, 2023, as well as integration costs relating to our acquisition of youtheory which closed on July 19, 2022.

 
   
 

(3)

 
  

Current period expense mainly pertains to development costs associated with our IT system implementation to augment our system infrastructure. Unlike other system improvement projects with costs capitalized, due to its cloud-based nature, these system implementation costs are expensed accordingly.

 
   
 

(4)

 
  

This cost represents the post-closing amortization of the fair value increase of acquired inventories related to the April 28, 2023 transaction with our former distribution partner in China.

 
   
 

(5)

 
  

Costs pertaining to our LTIP, excluding PSUs granted to certain employees relating to business combinations.

 
   
 

(6)

 
  

The vesting of share-based compensation provides a tax benefit during the period in which the awards are settled.

 
 

 

 

  

  

  Investor and Media Contact Information:  
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×